Quarterly ResultJul 15, 2026, 11:32 AM
Elevance Health Q2 Diluted EPS $6.71, Revenue $50.47B; Restructuring
AI Summary
Elevance Health reported mixed results for Q2 2026, with total revenues increasing to $50.47 billion from $49.78 billion year-over-year. However, diluted earnings per share decreased to $6.71 from $7.72 in the prior year period. The company initiated an Operating Model Transformation Program, incurring $129 million in costs during the first six months of 2026, which impacted profitability. Despite this, net cash provided by operating activities significantly increased to $6.25 billion for the six-month period.
Key Highlights
- Q2 2026 diluted EPS decreased to $6.71 from $7.72 YoY.
- Q2 2026 total revenues increased to $50.47 billion from $49.78 billion YoY.
- Six months ended June 30, 2026, diluted EPS was $14.73, down from $17.33.
- Six months ended June 30, 2026, total revenues were $100.66 billion, up from $98.67 billion.
- Net cash provided by operating activities for six months was $6.25 billion, up from $3.07 billion.
- Incurred $129 million in costs for the Operating Model Transformation Program.
- Repurchased $1.36 billion of common stock during the six months.
Price Impact
More from ELV